Questions?
Let’s connect.



    BIOCAT, THE BIOREGION OF CATALONIA, as the data controller, will process your data in order to respond to your inquiry or request. You can access, rectify, and delete your data, as well as exercise other rights by consulting the additional and detailed information on data protection in our Privacy policy.







    Send

    TIL

    Back

    Lorem ipsum dolor sit amet, consectetur adipiscing elit.

    Lorem ipsum of Catalonia entrusted Biocat, as a neutral connector and catalyst of the life sciences ecosystem, with a strategic mission: to map all public and private agents working in Advanced Therapies (ATMPs) and to drive the creation of a Hub capable of orchestrating efforts and maximizing impact.

    Development Phases
    A
    01

    Discovery and optimization

    1
    1.1

    Cell origin selection

    Selection of CAR structure and gene construct is critical. This includes choosing between single or dual-CAR systems, selecting the appropriate scFv, costimulatory domain(s), linker, and transmembrane domain. Special attention must also be given to the promoter driving CAR expression, as it impacts the level and regulation of CAR expression, which can influence T cell activation, persistence, and safety.

    Discover the stakeholders
    Cell origin selection Stakeholders

    Selection of CAR structure and gene construct is critical. This includes choosing between single or dual-CAR systems, selecting the appropriate scFv, costimulatory domain(s), linker, and transmembrane domain. Special attention must also be given to the promoter driving CAR expression, as it impacts the level and regulation of CAR expression, which can influence T cell activation, persistence, and safety.

    Astra Zeneca
    Astra Zeneca
    Discover

    Lorem ipsum through four main lines of work:
    CAR-T in oncology

    CAR-T in oncology

    Discover

    Gene therapy development

    CAR-T in inflammatory diseases

    CAR-NK

    Autologous CAR-T